pioglitazone has been researched along with Blood Clot in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 7.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "It is evident from the present study that vildagliptin has an influence on the biomarkers linked to the progression of thrombosis and may delay thrombogenesis linked to DM." | 7.81 | Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. ( Akhtar, M; Khan, S; Najmi, AK; Panda, BP, 2015) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 7.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| "Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication." | 5.56 | Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020) |
| "We review the existing evidence and most recent data elucidating the various inflammatory and coagulation biomarkers that are elevated in T2DM leading to thrombosis as well as the anti-inflammatory, anticoagulant and antithrombotic mechanisms of pioglitazone and vildagliptin in addition to their effect on glucose metabolism that may halt the progression of atherothrombotic disease." | 4.89 | Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis. ( Akhtar, M; Imran, M; Khan, S; Najmi, AK; Pillai, KK, 2013) |
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 3.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "It is evident from the present study that vildagliptin has an influence on the biomarkers linked to the progression of thrombosis and may delay thrombogenesis linked to DM." | 3.81 | Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. ( Akhtar, M; Khan, S; Najmi, AK; Panda, BP, 2015) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 3.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| "Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication." | 1.56 | Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Waller, AP | 1 |
| Agrawal, S | 1 |
| Wolfgang, KJ | 1 |
| Kino, J | 1 |
| Chanley, MA | 1 |
| Smoyer, WE | 1 |
| Kerlin, BA | 1 |
| Merkulova, A | 1 |
| Mitchell, SC | 1 |
| Stavrou, EX | 1 |
| Forbes, GL | 1 |
| Schmaier, AH | 1 |
| Zhang, MD | 1 |
| Zhao, XC | 1 |
| Zhang, YH | 1 |
| Yan, YF | 1 |
| Wang, ZM | 1 |
| Lv, SZ | 1 |
| Zhao, QM | 1 |
| Khan, S | 4 |
| Panda, BP | 1 |
| Akhtar, M | 2 |
| Najmi, AK | 2 |
| Imran, M | 1 |
| Pillai, KK | 1 |
| Li, D | 1 |
| Chen, K | 1 |
| Sinha, N | 1 |
| Zhang, X | 1 |
| Wang, Y | 1 |
| Sinha, AK | 1 |
| Romeo, F | 1 |
| Mehta, JL | 1 |
| Bodary, PF | 1 |
| Vargas, FB | 1 |
| King, SA | 1 |
| Jongeward, KL | 1 |
| Wickenheiser, KJ | 1 |
| Eitzman, DT | 1 |
| Smyth, SS | 1 |
| Jennings, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Blood Clot
| Article | Year |
|---|---|
Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Anticoagulants; Blood Coagulation; Blood Coagulation | 2013 |
7 other studies available for pioglitazone and Blood Clot
| Article | Year |
|---|---|
Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.
Topics: Animals; Blood Coagulation; Child; Female; Glucocorticoids; Humans; Male; Nephrotic Syndrome; Piogli | 2020 |
Ponatinib treatment promotes arterial thrombosis and hyperactive platelets.
Topics: Animals; Antineoplastic Agents; Arteries; Biomarkers; Blood Platelets; Disease Models, Animal; Drug | 2019 |
Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography.
Topics: Animals; Biomarkers; Blood Glucose; C-Reactive Protein; Fluorodeoxyglucose F18; Hypoglycemic Agents; | 2015 |
Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
Topics: Adamantane; Administration, Oral; Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Prog | 2015 |
The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation.
Topics: Animals; Aorta; Endothelium, Vascular; Gene Expression Regulation; Hypoglycemic Agents; Ligands; Mal | 2005 |
Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Drug Evaluation, Preclinical; Glipizide; Insulin | 2005 |
PPARgamma agonists: a new strategy for antithrombotic therapy.
Topics: Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hyperglycemia; Hypoglycemic Agents; Pioglitazone | 2005 |